Zanosar

Zanosar treats pancreatic cancer. It can cause nausea and vomiting. It can also change your blood sugar levels. Women should not get pregnant while on this medication.

Zanosar Overview

Updated: 

Zanosar is a prescription medication used to treat cancer of the pancreas that has gotten worse or spread to other parts of the body. Zanosar belongs to a group of drugs called alkylating agents. These work by slowing or stopping the growth of cancer cells in your body.

This medication is available in an injectable form to be given directly into a vein (IV) by a healthcare professional.

Common side effects of Zanosar include nausea, vomiting, and diarrhea.

Patient Ratings for Zanosar

How was your experience with Zanosar?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Zanosar?

What are you taking Zanosar for?

Choose one
  • Other
  • Colorectal Neoplasms
  • Hodgkin Disease
  • Pancreatic Neoplasms

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Zanosar work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Zanosar to a friend?

Uses of Zanosar

Zanosar is a prescription medication used to treat cancer of the pancreas that has gotten worse or spread to other parts of the body.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Manufacturer

Zanosar Drug Class

Zanosar is part of the drug class:

Side Effects of Zanosar

Common side effects of Zanosar  include nausea, vomiting, and diarrhea.

This is not a complete list of this medication's side effects. Ask your doctor or pharmacist for more information.

Tell your doctor if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Zanosar Interactions

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take:

This is not a complete list of Zanosar drug interactions. Ask your doctor or pharmacist for more information.

Zanosar Precautions

Serious side effects have been reported with Zanosar including the following:

  • severe infusion site reactions (tissue lesions and necrosis)
  • Confusion, lethargy, and depression have been reported.
  • Severe kidney toxicity
  • Zanosar can cause drowsiness. Do not drive or operate heavy machinery until you know how this medicaiton affects you.

Do not take Zanosar if you are allergic to Zanosar or to any of its ingredients.

Zanosar Food Interactions

Medications can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of Zanosar, there are no specific foo

ds that you must exclude from your diet when receiving this medication.

Inform MD

Before taking Zanosar, tell your doctor about all of your medical conditions. Especially tell your doctor if you:

  • are allergic to Zanosar or to any of its ingredients
  • have kidney problems
  • are pregnant or breastfeeding

Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements.

Zanosar and Pregnancy

Tell your doctor if you are pregnant or plan to become pregnant.

The FDA categorizes medications based on safety for use during pregnancy. Five categories - A, B, C, D, and X, are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy.

This medication falls into category D. In animal studies, pregnant animals were given this medication and had some babies born with problems. No well-controlled studies have been done in humans. Therefore, this medication may be used if the potential benefits to the mother outweigh the potential risks to the unborn child.

Zanosar and Lactation

Tell your doctor if you are breastfeeding or plan to breastfeed.

It is not known if Zanosar crosses into human milk. Because many medications can cross into human milk and because of the possibility for serious adverse reactions in nursing infants with use of this medication, a choice should be made whether to stop nursing or stop the use of this medication. Your doctor and you will decide if the benefits outweigh the risk of using Zanosar.

Zanosar Usage

This medication is available in an injectable form to be given directly into a vein (IV) by a healthcare professional.
 

Zanosar Dosage

This medication is available in an injectable form to be dosed by a healthcare professional.

  • Daily Schedule: The recommended dose for daily intravenous (into the vein) use is 500 mg/m2 for 5 consecutive days every 6 weeks until maximum benefit or until treatment-limiting toxicity is observed.
  • Weekly Schedule: The recommended starting dose for weekly intravenous (into the vein) use  is 1000 mg/m2 at weekly intervals for the first 2 courses (weeks). In later courses, drug doses may be increased in those who have not achieved a response and who have not experienced significant toxicity. A SINGLE DOSE OF 1500 mg/m2 SHOULD NOT BE EXCEEDED.

Zanosar Overdose

If this medication is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.

Zanosar FDA Warning

Zanosar should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

A patient need not be hospitalized but should have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity. Renal toxicity is dose-related and cumulative and may be severe or fatal. Other major toxicities are nausea and vomiting which may be severe and at times treatment-limiting. In addition, liver dysfunction, diarrhea, and hematological changes have been observed in some patients. Zanosar is mutagenic. When administered parenterally, it has been found to be tumorigenic or carcinogenic in some rodents.

The physician must judge the possible benefit to the patient against the known toxic effects of this drug in considering the advisability of therapy with Zanosar. The physician should be familiar with the following text before making a judgment and beginning treatment.